DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the Chandra Bhagat Pharma Ltd (CBPL) share price today?

Chandra Bhagat Pharma Ltd (CBPL) is trading at ₹33.06 on the BSE, down 4.97% on the day. Source: DocStoX.

What is the PE ratio of Chandra Bhagat Pharma Ltd?

Chandra Bhagat Pharma Ltd has a price-to-earnings (PE) ratio of 29.0 in the Healthcare sector.

What is the market capitalisation of Chandra Bhagat Pharma Ltd?

Chandra Bhagat Pharma Ltd has a market capitalisation of approximately ₹25 crore.

Chandra Bhagat Pharma Ltd

CBPL·BSE·Healthcare

₹33.06▼ -1.73 (-4.97%)

Healthcare · Pharmaceuticals & Biotechnology

A steady, established business

52W₹30

₹5911%

Open

₹33.06

High

₹33.06

Low

₹33.06

Prev Close

₹34.79

Volume

2.0K

VWAP

₹33.06

Snapshot

Key fundamentals

Market Cap

₹25 Cr

P/E Ratio

29.00Fair

P/B Ratio

0.75

EPS

₹1.14

Book Value

₹43.90

ROE

9.67%Average

ROCE

6.00%Weak

Dividend Yield

0.00%

Debt / Equity

0.50Moderate

Face Value

₹10.00

52W High

₹59.00

52W Low

₹29.70

Sector

Healthcare

Industry

Pharmaceuticals & Biotechnology

Buy

None moatMedium uncertainty

Fair value estimate

₹40

▲ 19.5%upside

Trading at ₹33 — 20% below our estimate

BearFair valueBull

₹34₹40₹45

/100

Business quality — Watch the fundamentals

Growth 50Profitability 12Efficiency 0Valuation 64

Plain English

Our view

A steady, established business
Promoters hold a controlling stake

How we got there

Fair value methods

Residual income

3% ROE fading to 13% over ~3 yrs, on ₹44 book

₹38

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹45

Analyst target

No analyst coverage

—

Blended fair value₹40

What the numbers say

Investment thesis

Bull case

Promoters hold a controlling stake

Bear case

No notable red flags from the current metrics.

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

29.0Fair

Below 15× is value territory; above 35× prices in strong growth

ROE

9.7%Average

Above 15% is considered healthy for Indian equities

ROCE

6.0%Weak

Above 18% means capital is working hard

Debt/Eq

0.50Moderate

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹25 Cr

P/B

0.75

EPS

₹1.14

Div Yield

—

What changed

Recent changes

Foreign investors-0.6% stake last quarter
Promoters+0.83% stake last quarter

What matters

News impact

Overview

Valuation

Reasonable

P/E 29.0×

Growth

Shrinking

-1% rev CAGR

Profitability

Modest

9.7% ROE

Financial health

Comfortable

D/E 0.50

Momentum

N/A

No technicals

Today

Trading activity

Delivery %—

Turnover₹66,120 Cr

Trades2

VWAP₹33.06

Face value₹10.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

-1.1%

+10.4%

10Y

+3.8%

Profit

+43.4%

—

10Y

—

EPS

+18.8%

+52.0%

10Y

-13.2%

Profile

Pros

Company has reduced debt.
Stock is trading at 0.75 times its book value
Promoter holding has increased by 0.83% over last quarter.

Watch-outs

Cons

Though the company is reporting repeated profits, it is not paying out dividend
The company has delivered a poor sales growth of 10.5% over past five years.
Company has a low return on equity of 5.92% over last 3 years.
Earnings include an other income of Rs.3.35 Cr.
Company has high debtors of 171 days.

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 31 Mar 2026

Promoters raised their stake by 0.83 pts; foreign investors sold 0.61 pts last quarter. The QoQ column shows each group's change versus the prior quarter.

73%

Promoter

Promoters

73.0%+0.83

Public

11.3%-0.51

FII / FPI

0.0%-0.61

DII

0.0%0.00

Others

15.7%

Total shareholders

280-21 QoQ

Quarterly trend

Ownership over time

Q4 FY26

Promoter73.02%

Public11.33%

Others15.65%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

Incorporated in 2003, Chandra Bhagat Pharma Ltd manufactures chemical and pharmaceutical products.[1]